Skip to main
ALMS
ALMS logo

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc. is positioned favorably in the biopharmaceutical sector with a promising pipeline that includes several compounds targeting autoimmune disorders, supported by a robust precision data analytics platform. The company has projected peak sales of $2 billion for its lead candidate in systemic lupus erythematosus (SLE), with conservative estimates attributing a 20% probability of regulatory approval, indicating significant revenue potential if successful. Additionally, while no value is currently assigned to ESK-001's sales in psoriatic arthritis, the viability of this indication is bolstered by positive data from similar therapies, further enhancing Alumis's growth prospects.

Bears say

Alumis Inc faces several significant risks that contribute to a negative outlook on its stock. Key risks include the potential inability to advance its lead candidate, ESK-001, into pivotal trials in a timely manner and the possibility of failing to demonstrate compelling efficacy for targeted autoimmune conditions. Additionally, challenges such as delays in regulatory submissions, the necessity for market approvals, competitive pressures in the immunology and inflammation (I&I) space, and a slower-than-expected market uptake compound investor concerns regarding the company's financial stability and growth prospects.

Alumis Inc (ALMS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 5 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.